PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.
Evidence
Neoadjuvant CT & Immunotherapy in HR+/HER2-negative breast cancer
Journal of Clinical Oncology, April 9, 2024 Presenter: Rios-Hoyo et al.
Read MoreIMPRINT-TN: Triple-Negative Breast Cancer, Unlikely to Respond to Immunotherapy
2024 European Breast Cancer Conference (EBCC) (Abstract 2LBA) Presenter: Wolf et al.
Read MoreEBCC 2024: The New Era of Genomic Testing in Early Stage Breast Cancer
EBCC 2024, Oral Presentation Presenter: Dr. Caroline Drukker
Read MoreMammaPrint + BluePrint predict anthracycline chemosensitivity, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 36 Authors: Audeh et al.
Read MorePrediction of chemotherapy benefit by MammaPrintยฎ, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 29 Authors: Audeh et al.
Read MoreAPHINITY (BIG 4-11) Trial: BluePrint prediction of CT Benefit w/ HER2-positive
APHINITY Trial (BIG 4-11) Authors: Krop, Piccart, et al
Read MoreMammaPrint + BluePrint predict pCR after NCT-FLEX, O’Shaughnessy et al., SABCS 2023 Abstract
SABCS 2023, PO5-15-04 Authors: O'Shaughnessy et al.
Read More